Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Travoprost 0.004% PQ ophthalmic solution
Travoprost 0.004% PQ · 1 trial · 3 indications
IOP (fluid pressure inside the eye) was assessed using a calibrated tonometer and measured in millimeters of mercury (mmHg). A higher IOP can be a greater risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage). One eye from each participant was chosen as the study eye and only the study eye was used for analysis.
| Arm | Type | Description |
|---|---|---|
| Travoprost | EXPERIMENTAL | Travoprost 0.004% PQ ophthalmic solution, 1 drop administered in each eye in the evening with travoprost vehicle administered once daily in the morning for 3 months |
| Timolol | ACTIVE_COMPARATOR | Timolol, 0.5% or 0.25% ophthalmic solution, 1 drop administered in each eye twice daily (once in the morning and once in the evening) for 3 months |
| Name | Type | Description |
|---|---|---|
| Travoprost 0.004% PQ ophthalmic solution | DRUG | - |
| Timolol, 0.5% or 0.25% ophthalmic solution | DRUG | Patients 2 months to \< 3 years of age received 0.25% |
| Travoprost Vehicle | DRUG | Inactive ingredients used to maintain masking |
Inclusion Criteria: * Diagnosis of pediatric glaucoma or ocular hypertension. * Qualifying mean IOP at the Eligibility Visit in at least one eye. * Written informed consent, including assent when applicable, MUST be obtained from the parent or legally authorized representative prior to any procedur...
Travoprost 0.004% PQ is an investigational ophthalmic solution being developed by Alcon Inc. (ticker: ALC) for pediatric glaucoma, including elevated intraocular pressure and ocular hypertension in pediatric patients. It is a small molecule formulation in Phase 3 development and is also known as Travoprost 0.004% PQ ophthalmic solution.
Travoprost 0.004% PQ is being studied for pediatric glaucoma, specifically for elevated intraocular pressure and ocular hypertension in pediatric patients. The Phase 3 trial enrolled patients as young as 2 months of age. It is investigational and has not been established as a treatment for this population.
Travoprost 0.004% PQ targets PTGFR, the prostaglandin F receptor, and acts as an agonist at that receptor. This receptor activity is the basis for its development as an intraocular pressure-lowering ophthalmic agent in pediatric patients with glaucoma or ocular hypertension.
Travoprost 0.004% PQ is developed by Alcon Inc., which trades under the ticker ALC. Alcon is the sponsor of the clinical program evaluating this ophthalmic solution in pediatric glaucoma patients.
Travoprost 0.004% PQ is in Phase 3 development. The program includes one completed Phase 3 trial, and no trials are currently listed as active. The drug remains investigational and is not approved for pediatric glaucoma.
Travoprost 0.004% PQ has been evaluated in the Phase 3 trial NCT01652664, titled Study of Travoprost Ophthalmic Solution, 0.004% Compared to Timolol (0.5% or 0.25%) in Pediatric Glaucoma Patients. The completed trial enrolled 184 patients, was randomized, double-blind, and active-controlled.
Yes, Travoprost 0.004% PQ and Travoprost 0.004% PQ ophthalmic solution refer to the same Alcon Inc. product candidate. The ophthalmic solution name describes the formulation used in the Phase 3 pediatric glaucoma program.